Published in Med Clin (Barc) on November 27, 2004
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Effectiveness of blood pressure control outside the medical setting. Hypertension (2006) 4.38
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
[Use of antihypertensive drug therapy and risk of development of congestive heart failure]. Med Clin (Barc) (2004) 2.03
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry. J Hypertens (2014) 1.97
Blood pressure variability and silent cerebral damage in essential hypertension. Am J Hypertens (2004) 1.69
Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertens (2002) 1.62
Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. J Hypertens (2007) 1.62
Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens (2007) 1.60
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. Hypertension (2012) 1.55
Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res (2011) 1.52
Cardiovascular morbidity and mortality and left ventricular geometric patterns in hypertensive patients treated in primary care. Rev Esp Cardiol (2009) 1.48
Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension (2011) 1.47
Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J (2011) 1.31
Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). Circulation (2010) 1.22
Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep (2011) 1.21
The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med (2002) 1.14
Cerebral hemodynamics and silent cerebral white matter lesions in middle-aged essential hypertensive patients. Blood Press (2004) 0.98
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens (2006) 0.96
[Cardiovascular risk profile of uncontrolled hypertensive patients. The Control-Project study]. Med Clin (Barc) (2007) 0.96
Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens (2014) 0.96
Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol (2006) 0.94
First Brazilian position on resistant hypertension. Arq Bras Cardiol (2012) 0.94
Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J Hypertens (2010) 0.94
Increased levels of atherosclerosis markers in salt-sensitive hypertension. Am J Hypertens (2006) 0.93
Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens (2012) 0.93
Salt intake, endothelial dysfunction, and salt-sensitive hypertension. J Clin Hypertens (Greenwich) (2002) 0.92
Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens (2004) 0.92
Quick diagnosis units: a potentially useful alternative to conventional hospitalisation. Med J Aust (2009) 0.91
Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis (2013) 0.91
Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press (2011) 0.91
Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol (2008) 0.90
Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag (2008) 0.90
Diabetes and stroke prevention: a review. Stroke Res Treat (2012) 0.89
Silent cerebral white matter lesions and cognitive function in middle-aged essential hypertensive patients. Am J Hypertens (2004) 0.89
Oral insulin-mimetic compounds that act independently of insulin. Diabetes (2007) 0.88
White matter lesions and cognitive impairment as silent cerebral disease in hypertension. ScientificWorldJournal (2006) 0.88
Prevalence of masked hypertension and associated factors in normotensive healthcare workers. Blood Press Monit (2013) 0.88
Cerebral folate deficiency syndromes in childhood: clinical, analytical, and etiologic aspects. Arch Neurol (2011) 0.88
High blood pressure, alcohol and cardiovascular risk. J Hypertens (2005) 0.87
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press (2007) 0.86
Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther (2003) 0.86
Association of the G protein beta3 subunit T allele with insulin resistance in essential hypertension. Clin Exp Hypertens (2002) 0.86
Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. J Hypertens (2013) 0.85
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens (2014) 0.85
Primary care referrals of patients with potentially serious diseases to the emergency department or a quick diagnosis unit: a cross-sectional retrospective study. BMC Fam Pract (2014) 0.84
Connecting cerebral white matter lesions and hypertensive target organ damage. J Aging Res (2011) 0.84
Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. Hypertension (2002) 0.84
Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther (2014) 0.84
Correlation between silent cerebral white matter lesions and left ventricular mass and geometry in essential hypertension. Am J Hypertens (2002) 0.83
Ergo-anthropometric assessment. Mayo Clin Proc (2009) 0.83
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens (2016) 0.83
Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens (2005) 0.83
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg (2016) 0.82
Analysis of cerebrospinal fluid γ-aminobutyric acid by capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis (2014) 0.82
ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev (2014) 0.82
[Factors predicting a short length of stay for acute exacerbations of chronic obstructive pulmonary disease]. Med Clin (Barc) (2005) 0.82
[Obesity, physical activity and cardiovascular risk: ergoanthropometric classification, pharmacological variables, biomarkers and "obesity paradox"]. Med Clin (Barc) (2009) 0.82
Clinical characteristics of isolated clinic hypertension. J Hypertens (2008) 0.82
Target organ damage: how to detect it and how to treat it? J Hypertens Suppl (2009) 0.82
The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs (2009) 0.81
ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens (2002) 0.81
Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. Medicine (Baltimore) (2010) 0.81
Magnitude of the white-coat effect in the community pharmacy setting: the MEPAFAR study. Am J Hypertens (2011) 0.81
Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc (2013) 0.80
Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press (2007) 0.80
Quick diagnosis units or conventional hospitalisation for the diagnostic evaluation of severe anaemia: a paradigm shift in public health systems? Eur J Intern Med (2011) 0.80
Gender differences in office and ambulatory control of hypertension. Am J Med (2008) 0.80
[Prevalence of masked hypertension in a cohort of controlled hypertensive patients in Spain]. Med Clin (Barc) (2011) 0.79
Outpatient Quick Diagnosis Units for the evaluation of suspected severe diseases: an observational, descriptive study. Clinics (Sao Paulo) (2011) 0.79
Lipophilic antioxidants in patients with phenylketonuria. Am J Clin Nutr (2003) 0.79
Aldosterone excess or escape: Treating resistant hypertension. J Clin Hypertens (Greenwich) (2009) 0.79
Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. Blood Press (2009) 0.79
Combination therapy in hypertension. Adv Ther (2013) 0.78
Ubiquinone-10 content in lymphocytes of phenylketonuric patients. Clin Biochem (2002) 0.78
Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens (2014) 0.78
A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem (2004) 0.78
[Differences between office and ambulatory control of hypertension in very elderly patients. The CARDIORISC - MAPAPRES project]. Med Clin (Barc) (2009) 0.78
Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. J Hypertens (2016) 0.78
Blood pressure control in the hypertensive population. What else the doctor can do? J Hypertens (2010) 0.78
Hypertension and mild cognitive impairment. Curr Hypertens Rep (2012) 0.78
Effects of alcohol withdrawal on 24 hour ambulatory blood pressure among alcohol-dependent patients. Alcohol Clin Exp Res (2003) 0.78
Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) (2007) 0.78